AstraZeneca is likely to run an additional global trial to assess the efficacy of its Covid-19 vaccine, its chief executive Pascal Soriot was quoted as saying after questions over the results from its late-stage study.
Instead of adding the trial arm to an ongoing US process, a new study would be run to evaluate a lower dosage that performed better than a full amount in AstraZeneca's studies, Mr Soriot was quoted as saying in a Bloomberg News report. "Now that we've found what looks like a better efficacy we have to validate this, so we need to do an additional study," Mr Soriot was quoted as saying in the report.
Mr Soriot said it would probably be another "international study, but this one could be faster because we know the efficacy is